Lufotrelvir (PF-07304814) is an antiviral drug developed by Pfizer which acts as a 3CL protease inhibitor.

[1] It is a prodrug with the phosphate group being cleaved in vivo to yield the active agent PF-00835231.

[2] Lufotrelvir is in human clinical trials for the treatment of COVID-19, and shows good activity against COVID-19 including several variant strains, but unlike the related drug nirmatrelvir it is not orally active and must be administered by intravenous infusion, and so has been the less favoured candidate for clinical development overall.

[3][4][5] This antiinfective drug article is a stub.

You can help Wikipedia by expanding it.